The mannose-binding lectin pathway can be activated by C3 hydrolysis or antigens without the presence of antibodies (non-specific immune response). In all three pathways, C3-convertase cleaves and ...

DNTH103 is a selective inhibitor of the active C1s protein in the complement system's classical pathway. Classical pathway activity is implicated in driving morbidity in a range of autoimmune ...

Importantly, there are three different ways complement can get activated. In the classical pathway it is activated by antibodies, so it is an antigen driven pathway.

DNTH103 is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically ...

Dianthus Therapeutics completes patient enrollment in phase 2 MaGic trial of DNTH103 in generalized myasthenia gravis New York Tuesday, May 6, 2025, 09:00 Hrs [IST] Dianthus Therapeutics, Inc., a ...

SEOUL, South Korea — ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its ...

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

The mannose-binding lectin pathway can be activated by C3 hydrolysis or antigens without the presence of antibodies (non-specific immune response). In all three pathways, C3-convertase cleaves and ...